A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- Safety/ Tolerability evaluation
研究概览
简要总结
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
详细描述
- Safety/ Tolerability evaluation
-Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
-
Pharmacokinetic Evaluation
-
Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted between 0 (pre-dose) and 96 hours after a single oral dose.
-
Blood sampling time pre-dose, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose
-
Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h
-
Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures
- •Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive)
- •A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight (kg) / {height (m)}2
- •Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)
排除标准
- •A subject with history of allergies including drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
- •A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
- •A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
- •A subject whose hemoglobin(Hb) level < 12 g/dL
- •A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL
- •A subject with HbA1c level ≥ 7.0 mmol/L
- •A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5 min sitting
- •A subject with history of drug abuse or positive urine drug screening test
- •A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.)
- •A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration
- •A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug
- •A subject who consumes more than 21 units of alcohol per week or unable to stop drinking throughout the study period.
- •A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months)
- •A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products
- •A subject with unusual dietary habit
- •A subject who was previously assigned to treatment during this study
- •The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons.
研究组 & 干预措施
MB12066 10mg
干预措施: MB12066 (Drug)
MB12066 30mg
干预措施: MB12066 (Drug)
MB12066 100mg
干预措施: MB12066 (Drug)
MB12066 150mg
干预措施: MB12066 (Drug)
MB12066 200mg
干预措施: MB12066 (Drug)
placebo
干预措施: MB12066 (Drug)
结局指标
主要结局
Safety/ Tolerability evaluation
时间窗: from day-1 to day8-10
Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
次要结局
- Pharmacokinetic Evaluation(between 0 (pre-dose) and 96 hours after a single oral dose.)